| |
Number of patients (percentage)
|
p value
|
|---|
|
CCLG
|
GPOH
|
|---|
|
N = 210
|
N = 437
|
|---|
|
Gender
|
|
Female
|
84 (40)
|
177 (40)
|
0.90
|
|
Male
|
126 (60)
|
260 (60)
|
|
Age (approx quartiles) (years)
|
|
0–9
|
34 (16)
|
94 (22)
|
0.17
|
|
10–14
|
74 (35)
|
123 (28)
|
|
15–19
|
58 (28)
|
115 (26)
|
|
20–35
|
44 (21)
|
105 (24)
|
|
Primary site
|
|
Central axis
|
84 (40)
|
236 (54)
|
< 0.001 (0.004)
|
|
Extremity
|
115 (55)
|
197 (45)
|
|
Unknown
|
11 (5)
|
4 (1)
|
|
Axial skeletal
|
26 (12)
|
89 (20)
|
|
Spine
|
7 (3
|
30 (7)
|
|
Pelvis
|
51 (24)
|
117 (27)
|
|
Limb proximal
|
61 (29)
|
103 (23)
|
|
Limb distal
|
54 (26)
|
94 (22)
|
|
Unknown
|
11 (5)
|
4 (1)
|
|
Volume
|
|
< 100 ml
|
57 (27)
|
117 (27)
|
0.48 (0.97)
|
|
≥ 100 ml
|
149 (71)
|
304 (69)
|
|
Unknown
|
4 (2)
|
16 (4)
|
|
Metastases
|
|
No
|
150 (71)
|
329 (75)
|
0.27 (0.41)
|
|
Yesd
|
56 (27)
|
105 (24)
|
|
Unknown
|
4 (2)
|
3 (1)
|
|
Histology
|
|
Ewing’s sarcoma
|
140 (67)
|
261 (60)
|
< 0.001 (< 0.001)
|
|
Atypical Ewing’s
|
8 (4)
|
70 (16)
|
|
PNET
|
43 (20)
|
101 (23)
|
|
Othera
|
6 (3)
|
5 (1)
|
|
Unknown
|
13 (6)
|
0 (0)
|
|
Risk group
|
|
Standard (SR)
|
53 (25)
|
102 (23)
|
0.60
|
|
High (HR)
|
157 (75)
|
335 (77)
|
|
Trial treatment
|
|
SR-VACA
|
27 (13)
|
52 (12)
|
0.96
|
|
SR-VAIA
|
26 (12)
|
50 (11)
|
|
HR-VAIA
|
76 (36)
|
164 (38)
|
|
HR-EVAIA
|
81 (39)
|
171 (39)
|
|
Histological responsec
|
|
Good
|
52 (25) [58]
|
78 (18) [65]
|
< 0.001 [0.33]
|
|
Poor
|
37 (18) [42]
|
42 (10) [35]
|
|
No surgery
|
103 (49)
|
111 (25)
|
|
NAb
|
3 (1)
|
200 (46)
|
|
Unknown
|
15 (7)
|
6 (1)
|
|
No. of chemotherapy cycles received
|
|
1–4
|
18 (8.6)
|
26 (6.0)
|
0.32
|
|
5–9
|
22 (10.5)
|
62 (14.2)
|
|
10–13
|
36 (17.10
|
83 (19.0)
|
|
14
|
131 (62.4)
|
254 (58.2)
|
|
Unknown
|
3 (1.4)
|
12 (2.8)
|
- p values including unknown data; the p values in brackets exclude unknown data
- aOsteosarcoma or soft tissue
- bNA not applicable, i.e. patients with early radiotherapy before surgery
- cThe numbers in square brackets are based only on patients with a good or poor response
- dThe proportions of patients with bone or bone marrow metastases were similar: 8% GPOH and 5% CCLG
